Cero Therapeutics Holdings Inc.
CERO
We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Our proprietary approach to T cell engineering, which enables us to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoir…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$7M
Op. Margin
–
ROIC
–
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (FY)
-$16M
Net Debt
$16M
Cash & Equiv.
$456K
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CERO
Cero Therapeutics Holdings (CERO) in two numbers
Questions about Cero Therapeutics Holdings
Does Cero Therapeutics Holdings (CERO) pay a dividend, and how much?
Yes. Cero Therapeutics Holdings (CERO) pays a dividend: $0.03 per share over the last twelve months, a dividend yield of 3.15% at the latest close. The Dividends tab has the full payment history and the safety score.
Source: 10-Q filed 13 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in CERO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CERO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.